Cite
HARVARD Citation
Matsuzaki, S. et al. (2018). Anti‐glypican‐1 antibody‐drug conjugate exhibits potent preclinical antitumor activity against glypican‐1 positive uterine cervical cancer. International journal of cancer. 142 (5), pp. 1056-1066. [Online].